Corrigendum to “Apremilast prevent doxorubicin-induced apoptosis and inflammation in heart through inhibition of oxidative stress mediated activation of NF-κB signaling pathways” (Pharmacological Reports (2018) 70(5) (993–1000), (S1734114017306679), (10.1016/j.pharep.2018.03.009))

Faisal Imam, Naif O. Al-Harbi, Mohammad Matar Al-Harbi, Mushtaq Ahmad Ansari, Abdullah F. Al-Asmari, Mohd Nazam Ansari, Wael A. Al-Anazi, Saleh Bahashwan, Mashal M. Almutairi, Musaad Alshammari, Mohammad Rashid Khan, Abdulaziz Mohammed Alsaad, Moureq Rashed Alotaibi

Pharmacology

Research output: Contribution to journal › Comment/debate

Fingerprint

Dive into the research topics of 'Corrigendum to “Apremilast prevent doxorubicin-induced apoptosis and inflammation in heart through inhibition of oxidative stress mediated activation of NF-κB signaling pathways” (Pharmacological Reports (2018) 70(5) (993–1000), (S1734114017306679), (10.1016/j.pharep.2018.03.009))'. Together they form a unique fingerprint.

Corrigendum to “Apremilast prevent doxorubicin-induced apoptosis and inflammation in heart through inhibition of oxidative stress mediated activation of NF-κB signaling pathways” (Pharmacological Reports (2018) 70(5) (993–1000), (S1734114017306679), (10.1016/j.pharep.2018.03.009))

Fingerprint

Medicine and Dentistry

Nursing and Health Professions